Karyopharm receives positive chmp opinion for nexpovio® (selinexor) for the treatment of patients with refractory multiple myeloma

Newton, mass., jan. 29, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a...
KPTI Ratings Summary
KPTI Quant Ranking